These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 2130488)

  • 1. [Laboratory findings in patients with melanoma].
    Jandová E; Simková M; Horcicko J
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1990; 33(4):447-50. PubMed ID: 2130488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical markers of malignant melanoma.
    Matous B; Cigánek EF; Budĕsínská A; Duchon J
    Neoplasma; 1987; 34(1):77-84. PubMed ID: 3104808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum zinc levels are increased in melanoma patients.
    Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
    Melanoma Res; 1998 Jun; 8(3):273-7. PubMed ID: 9664150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein D expression in cutaneous malignant melanoma.
    Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
    J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of melanogenesis in malignant melanoma.
    Matous B; Bubnova E; Budesinska A; Kostirova M
    Sb Lek; 1994; 95(4):333-38. PubMed ID: 8867704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous measurement of circulating intercellular adhesion molecule-1 and serum copper zinc superoxide dismutase activity in patients with malignant melanoma.
    Wollina U; Karte K; Olbertz K; Hipler UC
    Oncol Rep; 1998; 5(2):473-6. PubMed ID: 9468582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high percentage of skin melanoma cells expresses SPANX proteins.
    Salemi M; Calogero AE; Vicari E; Migliore E; Zaccarello G; Cosentino A; Amore M; Tricoli D; Castiglione R; Bosco P; Rappazzo G
    Am J Dermatopathol; 2009 Apr; 31(2):182-6. PubMed ID: 19318807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis.
    Pećina-Slaus N; Zigmund M; Kusec V; Martić TN; Cacić M; Slaus M
    J Cutan Pathol; 2007 Mar; 34(3):239-46. PubMed ID: 17302608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas.
    Attis MG; Burchette JL; Selim MA; Pham T; Soler AP
    Hum Pathol; 2006 Jul; 37(7):899-905. PubMed ID: 16784991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of epidemiological characteristics of malignant melanoma during the years 1962-1972 and 1983-1986 in the Federal Republic of Germany.
    Garbe C; Wiebelt H; Orfanos CE
    Dermatologica; 1989; 178(3):131-5. PubMed ID: 2656326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
    de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
    Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
    Eyden B; Pandit D; Banerjee SS
    Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins.
    Miettinen M; Franssila K
    Lab Invest; 1989 Dec; 61(6):623-8. PubMed ID: 2481151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acral-lentiginous melanoma: the newest subgroup of malignant melanomas of the skin].
    Panizzon R; Stieger M; Schüler G; Hardmeier T
    Schweiz Med Wochenschr; 1982 Apr; 112(17):612-8. PubMed ID: 7089511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E; Graef V; Ruppel R
    Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of galanin in melanocytic tumors].
    Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
    Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcl-2 protein expression in melanocytic neoplasms of the skin.
    Ramsay JA; From L; Kahn HJ
    Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis.
    Worcester EM; Coe FL; Evan AP; Parks JH
    BJU Int; 2006 Jun; 97(6):1285-90. PubMed ID: 16686727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.